Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre

Richard B. Warren; Benjamin Brown; D. Lavery; Christopher Em Griffiths

doi:10.1111/j.1365-2133.2010.09986.x

Abstract

1 min read

In a cohort of U.K. patients with severe psoriasis, adalimumab has proved to be a significant addition to the expanding armamentarium of biologics for psoriasis. Pharmacovigilance, in the form of registries, is essential to assess the long-term safety of such drugs.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2008

Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre

Richard B. Warren, Benjamin Brown, D. Lavery, Darren M. Ashcroft, Christopher Em Griffiths

Editorial Material2012

Biologics for psoriasis: current evidence and future use

Christopher Em Griffiths

Article2023

004 Does methotrexate affect treatment persistence or effectiveness of adalimumab for psoriasis? A trial emulation cohort study

Zenas Z N Yiu, Catherine Smith, Philip Laws, Philip Hampton, Christopher Em Griffiths, Richard B. Warren

Article2014

Baseline characteristics of patients with psoriasis enrolled in the British Association of Dermatologists' Biologic Interventions Register.

Ireny Iskandar, Richard B. Warren, Zenas Z N Yiu, Jnwn Barker, David Burden, A.D. Ormerod, Nick J. Reynolds, Catherine Smith, Christopher Em Griffiths, Darren M. Ashcroft

Article2025

Adalimumab Monotherapy vs Adalimumab With Methotrexate for Psoriasis

Zenas Z N Yiu, Catherine Smith, Philip Laws, Philip Hampton, Christopher Em Griffiths, Richard B. Warren